Oral treatment with a nutraceutical (Cosequin) for ameliorating signs of navicular syndrome in horses.
Fourteen horses with a progressive forelimb lameness of 3 to 12 months' duration, diagnosed as navicular syndrome, were selected from clinical cases admitted to Auburn University Equine Hospital for evaluation of the efficacy of an orally administered nutraceutical (Cosequin, Nutramax Laboratories, Inc., Edgewood, MD) for ameliorating clinical signs associated with naturally occurring navicular syndrome. Horses were randomly allocated to treatment with the nutraceutical or a placebo. Treatment was five scoops (16.5 g) of powder twice daily in the feed. The test group (n = 8) received a patented nutraceutical consisting of 9 g of FCHG49 (a highly purified glucosamine HCl), 3 g of TRH122 (a specific purified low-molecular-weight sodium chondroitin sulfate), and 600 mg of manganese ascorbate. The placebo group (n = 6) received an indistinguishable oral powder containing only excipients. Owners and the investigator were unaware of group assignments. The same investigator assessed lameness and overall clinical condition at enrollment and after 4 and 8 weeks of treatment. Lameness was assessed by an algofunctional lameness index, comprising a combined sum score of standing posture, hoof tester examination, and lameness scores at various levels of work. Overall clinical efficacy was rated on a visual analogue scale. Owners assessed lameness via a preassigned questionnaire, incorporating an algofunctional lameness index and overall clinical condition at weekly intervals. Radiographic examinations of the navicular bones were performed at enrollment and after 8 weeks of treatment. The median algofunctional lameness index and overall clinical condition scores assigned the investigator were significantly improved (P = .05) for horses treated with the nutraceutical compared with placebo-treated horses. The degree of improvement in algofunctional lameness index assigned by owners after 8 weeks was also significant (P = .045) between the treatment groups. Radiographic scores after treatment were not significantly different between the groups (P > .05).
Hanson
R R
RR
Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, AL 36849, USA.
Brawner
W R
WR
Blaik
M A
MA
Hammad
T A
TA
Kincaid
S A
SA
Pugh
D G
DG
D000818:Animals; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000627:therapeutic use*; D019587:Dietary Supplements; D005260:Female; D005534:Foot Diseases / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D005944:Glucosamine / Q000008:administration & dosage / Q000627:therapeutic use*; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D007794:Lameness, Animal / Q000188:drug therapy*; D008297:Male; D008345:Manganese / Q000008:administration & dosage / Q000627:therapeutic use*
D008345:Manganese; D002809:Chondroitin Sulfates; D005944:Glucosamine